



MARICO LIMITED

PART I

(Rs. in Lacs)

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2012.

Particulars	Quarter ended		Year ended		Particulars	Quarter ended		Year ended	
	June 30, 2012 (Unaudited)	March 31, 2012 (Unaudited)	June 30, 2011 (Unaudited)	March 31, 2012 (Audited)		June 30, 2012 (Unaudited)	March 31, 2012 (Unaudited)	June 30, 2011 (Unaudited)	March 31, 2012 (Audited)
1 Income from operations					1. Segment Revenue (Note 4)				
a. Net Sales / Income from Operations (Net of excise duty)	126,720.75	90,936.94	104,139.51	396,819.71	(a) Consumer Products				
b. Other operating income	311.97	379.00	187.09	1,146.91	i. Domestic	93,419.91	62,049.32	76,229.79	276,594.05
Total income from operations (net)	127,032.72	91,315.94	104,326.60	397,966.62	ii. International	25,550.05	21,821.38	21,832.84	93,545.54
2. Expenses					(b) Skin Care	118,969.96	83,870.70	98,062.63	370,139.59
a. Cost of materials consumed	55,922.42	51,890.62	52,809.30	214,101.33		8,062.76	7,445.24	6,263.97	27,827.03
b. Purchases of stock-in-trade	5,137.40	433.89	577.13	1,744.35	Sub - total	127,032.72	91,315.94	104,326.60	397,966.62
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade (Increase) / decrease	3,048.71	(9,484.99)	6,134.19	(5,078.08)	Less: Inter Segment revenue	-	-	-	-
d. Employee benefits expenses	9,473.85	8,361.87	7,053.70	30,728.85	Net Sales / Income from Operations	127,032.72	91,315.94	104,326.60	397,966.62
e. Depreciation and amortization expense	1,932.80	1,906.06	1,689.76	7,252.28					
f. Advertisement & Sales Promotion	15,585.28	11,307.11	9,724.39	42,581.89	2. Segment Result (Note 4)				
g. Other expenses	19,076.00	17,550.05	15,331.96	65,449.16	(Profit before Interest and Tax and exceptional items)				
Total Expenses	110,176.46	81,964.61	93,320.43	356,779.78	(a) Consumer Products				
3 Profit from operations before other income, finance costs and exceptional items (1-2)	16,856.26	9,351.33	11,006.17	41,186.84	i. Domestic	18,506.66	10,858.74	11,824.23	44,428.04
4 Other Income	1,450.95	790.59	728.18	3,257.38	ii. International	1,706.29	1,311.84	1,622.12	7,993.44
5 Profit from ordinary activities before finance costs and exceptional items (3+4)	18,307.21	10,141.92	11,734.35	44,444.22	(b) Skin Care	(725.90)	(380.42)	(558.06)	(2,907.32)
6 Finance costs	1,702.53	1,130.59	980.06	4,238.23	Sub - total	19,487.05	11,790.16	12,888.29	49,514.16
7 Profit from ordinary activities after finance costs but before Exceptional Items (5-6)	16,604.68	9,011.33	10,754.29	40,205.99	Less: Interest (net)	1,118.88	722.15	536.70	2,482.80
8 Exceptional items (Note 8)	-	(175.28)	-	(175.28)	Add: Un-allocable income	527.66	420.70	258.22	1,215.15
9 Profit from ordinary activities before Tax (7+8)	16,604.68	8,836.05	10,754.29	40,030.71	Less: Un-allocable expense	(2,291.15)	(2,477.38)	(1,855.52)	(8,040.52)
10 Tax expense (net of MAT credit entitlement)	4,026.36	1,887.63	2,103.28	7,824.42	Total Profit before Tax and Exceptional Items	16,604.68	9,011.33	10,754.29	40,205.99
11 Net Profit from ordinary activities after Tax (9-10)	12,578.32	6,948.42	8,651.01	32,206.29					
12 Extraordinary item (net of tax)	-	-	-	-	3. Capital Employed (Segment Assets - Segment Liabilities) (Note 4)				
13 Net Profit for the period / year (11-12)	12,578.32	6,948.42	8,651.01	32,206.29	(a) Consumer Products				
14 Share of profit / (loss) of associates	-	-	-	-	i. Domestic	143,514.88	64,013.90	52,338.19	64,013.90
15 Minority Interest	194.82	(21.29)	150.82	495.17	ii. International	58,183.85	59,342.91	52,462.64	59,342.91
16 Net Profit after taxes, minority interest and share of profit / (loss) of associates (13 ±14-15)	12,383.50	6,969.71	8,500.19	31,711.12	(b) Skin Care	201,698.73	123,356.81	104,800.83	123,356.81
17 Paid-up Equity Share Capital (Note 6) (Face Value: Re.1 per share)	6,445.22	6,149.34	6,146.16	6,149.34	Add: Unallocated Capital Employed	17,427.63	19,238.54	22,555.23	19,238.54
18 Reserves excluding Revaluation Reserves (as per Balance Sheet)				108,151.95		(44,326.63)	(28,294.06)	(27,814.84)	(28,294.06)
19 Earnings Per Share (EPS)						174,799.73	114,301.29	99,541.22	114,301.29
i EPS before Extraordinary items for the period / year									
(a) Basic	1.97	1.13	1.41	5.16					
(b) Diluted	1.96	1.13	1.41	5.15					
ii EPS after Extraordinary items for the period / year									
(a) Basic	1.97	1.13	1.41	5.16					
(b) Diluted	1.96	1.13	1.41	5.15					

PART II				
SELECT INFORMATION FOR THE QUARTER ENDED JUNE 30, 2012.				
Particulars	Quarter ended			Year ended
	June 30, 2012 (Unaudited)	March 31, 2012 (Unaudited)	June 30, 2011 (Unaudited)	March 31, 2012 (Audited)
A PARTICULARS OF SHAREHOLDING				
1 Public shareholding				
- Number of shares	258,983,479	229,195,867	228,314,930	229,195,867
- Percentage of shareholding	40.18	37.27	37.15	37.27
2 Promoters & Promoter Group Shareholding				
(a) Pledged / Encumbered				
- Number of Shares	-	-	400,000	-
- Percentage of Shares (as a % of total shareholding of promoters and promoter group)	-	-	0.10	-
- Percentage of Shares (as a % of total share capital of the company)	-	-	0.07	-
(b) Non-encumbered				
- Number of Shares	385,538,520	385,738,520	385,901,520	385,738,520
- Percentage of Shares (as a % of total shareholding of promoters and promoter group)	100.00	100.00	99.90	100.00
- Percentage of Shares (as a % of total share capital of the company)	59.82	62.73	62.78	62.73

PARTICULARS	Quarter Ended June 30, 2012
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	Nil
Received during the quarter	10
Disposed of during the quarter	10
Remaining unresolved at the end of the quarter	Nil

Notes to the Marico Limited Consolidated financial results:

1. The Consolidated un-audited financial results for the quarter ended June 30, 2012 were reviewed by the audit committee and approved by the Board of Directors of Marico Limited ("the Company") at their meeting held on August 3, 2012. These consolidated financial results for the quarter ended June 30, 2012 have been subjected to limited review by the statutory auditors of the Company.
2. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the Listing Agreement. The Standalone financial results, which were subjected to the Limited Review by the statutory auditors, are available on the Company's website - <http://www.marico.com> and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com).
3. The Consolidated financial results for the quarter ended June 30, 2012 comprise results of Marico Limited and its subsidiaries and step down subsidiaries in India, Bangladesh, UAE, Egypt, South Africa, Malaysia, Singapore and Vietnam. All the aforesaid entities are collectively called 'Marico'.
4. The primary reporting of Consolidated financial results of Marico is based on two business segments namely "Consumer Products" and "Skin Care". The Company has bifurcated the financial results of its Consumer product business segment into India Business and international Business, by way of providing supplementary information.

During the quarter, the Company has categorised certain corporate/ common expenses and assets/ liabilities as unallocable having regard to the nature of such items, which hitherto were allocated to consumer product business segment. Consequently previous period/ year figures have been reclassified to conform to the current period/ year figures.

5. During the quarter, on May 29th, 2012, the Company concluded the effective acquisition of the personal care business of Paras Pharmaceuticals Limited ("PPL") for a consideration of Rs. 74,560 lacs. The acquisition was effected through Marico Consumer Care Limited ("MCCL"), a wholly owned subsidiary of the Company. MCCL was incorporated on April 20, 2012 and acquired 100 % equity stake in Halite Personal Care India Private Limited ("Halite") from Halite's erstwhile owners. The personal care business had been demerged from PPL into Halite effective March 1, 2012 under a Scheme of amalgamation and arrangements approved by the High Court of Punjab and Haryana. The acquisition of Halite by MCCL resulted into Goodwill on consolidation of Rs. 12,041 lacs, which is the excess of consideration paid over the net worth of Halite on the date of acquisition. The said net worth includes goodwill of Rs. 61,610 lacs which under the aforesaid Court Scheme shall be tested for impairment. The consolidated financial results of Marico for the quarter ended June 30, 2012 include the financial results of MCCL and Halite from the relevant dates and hence are strictly not comparable with previous period / year figures.

6. The shareholders of the Company, at their meeting held on May 2, 2012, approved issue of equity shares on preferential allotment basis aggregating Rs. 50,000 lacs at a price of Rs. 170 per equity share to two overseas investors for funding a part of the Halite acquisition. Subsequently, the Company allotted 29,411,764 equity shares of face value Re. 1 each at a share premium of Rs. 169 each to these investors on 16th May 2012. This resulted in increase of Equity share capital by Rs. 294.12 lacs and Securities premium reserve by Rs. 49,705.88 lacs. The proceeds of the issue together with internal accruals were infused by Marico as equity investment in MCCL. MCCL utilized the equity proceeds for acquiring 100% equity stake in Halite on May 29, 2012.
7. Pursuant to the Announcement of the Institute of Chartered Accountants of India's ("ICAI") "Accounting for Derivatives" on encouraging the early adoption of Accounting Standard 30 ("AS 30"), "Financial Instruments: Recognition and Measurement", the Company had, commencing from the year ended March 31, 2009, decided on early adoption of AS 30 to the extent it does not conflict with existing mandatory accounting standards and other authoritative pronouncements, Company Law and other regulatory requirements. Accordingly, the net unrealised gain/ (loss) of Rs. (6,305.64) lacs as at June 30, 2012 [Rs. (3,392.52) lacs as at March 31, 2012 and Rs. 477.63 lacs as at June 30, 2011] in respect of outstanding derivative instruments and foreign currency loans at the period end which qualify for hedge accounting, stands in the 'Hedge Reserve', which would be recognised in the Statement of Profit and Loss on occurrence of the underlying transactions or forecast revenue.
8. Exceptional items for the quarter and year ended March 31, 2012 pertains to provision for impairment relating to Kaya Skin Clinics in India / Middle East.
9. Following are the particulars of the Company (on a standalone basis) :

(Rs. In Lacs)

	Quarter ended June 30, 2012	Quarter ended March 31, 2012	Quarter ended June 30, 2011	Year ended March 31, 2012
Net Sales / Income from Operations	97,212.35	67,582.61	80,380.96	295,821.05
Profit before tax	16,713.51	10,784.90	9,777.26	39,927.39
Profit after tax	13,335.53	8,770.84	8,161.65	33,658.43

10. During the quarter, the Company acquired commercial premises for a new office building at a consideration of Rs. 12,083.12 lacs.
11. Stock Options were granted up to June 30, 2012 to certain eligible employees of the Company pursuant to the "Marico Employees' Stock Options Scheme 2007" ("the Scheme"). In all, 11,376,300 options were granted up to June 30, 2012 of which 4,663,600 options have been forfeited and 6,110,235 options have been exercised. During the quarter ended June 30, 2012, pursuant to the exercise of the stock options, the Company has allotted 175,848 equity shares of Re. 1 each, respectively, to employees resulting in increase in paid-up share capital by Rs. 1.76 lacs and securities premium reserve by Rs. 95.83 lacs. As on June 30, 2012, 602,465 options were outstanding.

12. The current period figures in this Statement have been reported in the format recommended as per the SEBI circular dated April 16, 2012 .The comparative figures have also been accordingly restated to conform to the current period presentation.
13. These Financial Results and other related useful information are available on the Company's website - <http://www.marico.com>

Place: Mumbai

Harsh C. Mariwala

Date: August 3, 2012

Chairman & Managing Director

About Marico

Marico Limited (BSE: 531642, NSE: "MARICO") and its subsidiaries("Marico") constitute one of India's leading Consumer Products & Services Groups, in the global beauty and wellness space. During 2011-12, Marico recorded a turnover of Rs. 3980 Crore, through its products and services sold in India and about 25 other countries in Asia and Africa.

Marico touches the lives of 1 out of every 3 Indians, through its portfolio of brands such as Parachute, Parachute Advansed, Saffola, Hair & Care, Nihar, Mediker and Revive. The international consumer products portfolio contributes to about 24% of the Group's revenue, with brands like Parachute, HairCode, Fiancée, Camelia, Aromatic, Caivil, Hercules, Black Chic, Code 10, Ingwe, X-Men, L'Ovite and Thuán Phat. It is also present in the Skin Care solutions segment through Kaya Clinics in India, Middle East and Bangladesh and Derma Rx in Singapore.

Marico is widely recognized for its entrepreneurial culture and values of openness, trust and empowerment. Marico's endeavour is to transform the lives of all stakeholders by helping them maximize their true potential. The purpose is articulated in the true Mariconian spirit ... to.... "Be More. Every Day".

Marico's focus on sustainable profitable growth is manifest through its consistent financial performance, a CAGR of over 20% in both Turnover and Profits over the past 5 years. For more information, please visit www.marico.com

Marico believes in the power of "Green" Initiatives. Hence its endeavour is to maximise the use of the paperless electronic medium for sending its shareholders the Annual Report and other communication. We seek your help in this regard. Please therefore :

- update your email addresses with your respective Depository Participant (DP) where you hold your DEMAT accounts. or
- mail us at milinvrel@maricoindia.net with your email address, Name, DP ID and Client ID.

We thank you for your support in this Green Initiative.

Registered Office: "Rang Sharda", Krishnachandra Marg, Bandra Reclamation, Bandra (West), Mumbai - 400050, India.

Email: milinvrel@maricoindia.net

Websites: www.marico.com , www.saffolalife.com , www.kayaclinic.com , www.parachuteadvansed.com , and www.maricoinnovationfoundation.org



MARICO LIMITED

(Rs. in Lacs)				
PART I				
STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2012.				
Particulars	Quarter ended			Year ended
	June 30, 2012 (Unaudited)	March 31, 2012 (Unaudited)	June 30, 2011 (Unaudited)	March 31, 2012 (Audited)
1 Income from operations				
a. Net Sales / Income from Operations (Net of excise duty)	97,212.35	67,582.61	80,380.96	295,821.05
b. Other operating Income	248.72	232.98	76.57	714.33
Total Income from operations (net)	97,461.07	67,815.59	80,457.53	296,535.43
2. Expenses				
a. Cost of materials consumed	43,822.01	41,459.75	41,065.39	167,192.32
b. Purchases of stock-in-trade	7,242.97	3,205.01	2,604.03	10,632.60
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade (Increase) / decrease	2,633.21	(8,167.27)	6,301.20	(4,001.51)
d. Employee benefits expenses	4,277.55	3,216.82	3,150.93	12,620.83
e. Depreciation and amortization expense	770.68	840.68	713.29	3,148.94
f. Advertisement & Sales Promotion	10,384.52	7,643.42	7,119.60	29,593.50
g. Other expenses	11,714.45	10,651.94	9,633.38	39,752.00
Total expenses	80,845.39	58,850.35	70,587.82	258,938.68
3 Profit from operations before other income, finance costs and exceptional items (1-2)	16,615.68	8,965.24	9,869.71	37,596.75
4 Other Income	1,433.40	2,542.32	582.21	5,164.65
5 Profit from ordinary activities before finance costs and exceptional items (3+4)	18,049.08	11,507.56	10,451.92	42,761.41
6 Finance costs	1,335.57	722.65	674.65	2,834.02
7 Profit from ordinary activities after finance costs but before Exceptional Items (5-6)	16,713.51	10,784.90	9,777.26	39,927.39
8 Exceptional items	-	-	-	-
9 Profit from ordinary activities before Tax (7+8)	16,713.51	10,784.90	9,777.26	39,927.39
10 Tax expense (net of MAT credit entitlement)	3,377.98	2,014.06	1,615.61	6,268.96
11 Net Profit from ordinary activities after Tax (9-10)	13,335.53	8,770.84	8,161.65	33,658.43
12 Extraordinary item (net of tax)	-	-	-	-
13 Net Profit for the period / year (11-12)	13,335.53	8,770.84	8,161.65	33,658.43
14 Paid-up Equity Share Capital (Face value Re.1 per share) (Note 4)	6,445.22	6,149.34	6,146.16	6,149.34
15 Reserves excluding Revaluation Reserves (as per balance sheet)				106,264.14
16 Earnings Per Share (EPS) Not Annualised				
i EPS before Extraordinary items for the period / year				
(a) Basic	2.12	1.43	1.33	5.48
(b) Diluted	2.12	1.43	1.33	5.47
ii EPS after Extraordinary items for the period / year				
(a) Basic	2.12	1.43	1.33	5.48
(b) Diluted	2.12	1.43	1.33	5.47

PART II				
SELECT INFORMATION FOR THE QUARTER ENDED JUNE 30, 2012				
Particulars	Quarter ended			Year ended
	June 30, 2012 (Unaudited)	March 31, 2012 (Unaudited)	June 30, 2011 (Unaudited)	March 31, 2012 (Audited)
A PARTICULARS OF SHAREHOLDING				
1 Public Shareholding				
- Number of Shares	258,983,479	229,195,867	228,314,930	229,195,867
- Percentage of Shareholding	40.18	37.27	37.15	37.27
2 Promoters & Promoter Group Shareholding				
(a) Pledged / Encumbered				
- Number of Shares	-	-	400,000	-
- Percentage of Shares (as a % of total shareholding of promoters and promoter group)	-	-	0.10	-
- Percentage of Shares (as a % of total share capital of the company)	-	-	0.07	-
(b) Non-encumbered				
- Number of Shares	385,538,520	385,738,520	385,901,520	385,738,520
- Percentage of Shares (as a % of total shareholding of promoters and promoter group)	100.00	100.00	99.90	100.00
- Percentage of Shares (as a % of total share capital of the company)	59.82	62.73	62.78	62.73

PARTICULARS		Quarter Ended June 30, 2012	
B INVESTOR COMPLAINTS			
Pending at the beginning of the quarter		Nil	
Received during the quarter		10	
Disposed of during the quarter		10	
Remaining unresolved at the end of the quarter		Nil	

Notes to the Marico Limited Standalone financial results:

1. The Standalone un-audited financial results for the quarter ended June 30, 2012 were reviewed by the audit committee at its meeting held on August 3, 2012 and approved by the Board of Directors of Marico Limited ("the Company") at its meeting held on August 3, 2012. These financial results have been subjected to limited review by the statutory auditors of the Company.
2. The Company has only one reportable segments- "Consumer Products" - in terms of Accounting Standard 17 "Segment Reporting" mandated by Rule 3 of the Companies ("Accounting Standards") Rules, 2006.
3. During the quarter, on May 29th, 2012, the Company concluded the effective acquisition of the personal care business of Paras Pharmaceuticals Limited ("PPL") for a consideration of Rs. 74,560 lacs. The acquisition was effected through Marico Consumer Care Limited ("MCCL"), a wholly owned subsidiary of the Company. MCCL was incorporated on April 20, 2012 and acquired 100 % equity stake in Halite Personal Care India Private Limited ("Halite") from Halite's erstwhile owners. The personal care business had been demerged from PPL into Halite effective March 1, 2012 under a Scheme of amalgamation and arrangement approved by the High Court of Punjab and Haryana.
4. The shareholders of the Company, at their meeting held on May 2, 2012, approved issue of equity shares on preferential allotment basis aggregating Rs. 50,000 lacs at a price of Rs. 170 per equity share to two overseas investors for funding a part of the Halite acquisition. Subsequently, the Company allotted 29,411,764 equity shares of face value Re. 1 each at a share premium of Rs. 169 each to these investors on 16th May 2012. This resulted in increase of Equity share capital by Rs. 294.12 lacs and Securities premium reserve by Rs. 49,705.88 lacs. The proceeds of the issue together with internal accruals were infused by Marico as equity investment in MCCL. MCCL utilized the equity proceeds for acquiring 100% equity stake in Halite on May 29, 2012.
5. Pursuant to the Announcement of the Institute of Chartered Accountants of India's ("ICAI") "Accounting for Derivatives" on encouraging the early adoption of Accounting Standard 30 ("AS 30"), "Financial Instruments: Recognition and Measurement", the Company had, commencing from the year ended March 31, 2009, decided on early adoption of AS 30 to the extent it does not conflict with existing mandatory accounting standards and other authoritative pronouncements, Company Law and other regulatory requirements. Accordingly, the net unrealised gain/ (loss) of Rs. (6,305.64) lacs as at June 30, 2012 [Rs. (3,392.52) lacs as at March 31, 2012 and Rs. 477.63 lacs as at June 30, 2011] in respect of outstanding derivative instruments and foreign currency loans at the period end which qualify for hedge accounting, stands in the 'Hedge Reserve', which would be recognised in the Statement of Profit and Loss on occurrence of the underlying transactions or forecast revenue.

6. Stock Options were granted up to June 30, 2012 to certain eligible employees of the Company pursuant to the "Marico Employees' Stock Options Scheme 2007" ("the Scheme"). In all, 11,376,300 options were granted up to June 30, 2012 of which 4,663,600 options have been forfeited and 6,110,235 options have been exercised. During the quarter ended June 30, 2012, pursuant to the exercise of the stock options, the Company has allotted 175,848 equity shares of Re. 1 each, to employees resulting in increase in paid-up share capital by Rs. 1.76 lacs and Securities premium reserve by Rs. 95.83 lacs. As on June 30, 2012, 602,465 options were outstanding.
7. During the quarter, the Company acquired commercial premises for a new office building at a consideration of Rs. 12,083.12 lacs.
8. The current period figures in this Statement have been reported in the format recommended as per the SEBI circular dated April 16, 2012. The comparative figures have also been accordingly restated to conform to the current period presentation.
9. These Financial Results and other related useful information are available on Marico's website - <http://www.marico.com>

Place: Mumbai

Harsh C. Mariwala

Date: August 3, 2012

Chairman & Managing Director